Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for mirabegron

  1. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  2. Vibegron for treating symptoms of overactive bladder syndrome (TA999)

    Evidence-based recommendations on vibegron (Obgemsa) for treating symptoms of overactive bladder syndrome in adults.

    Technology appraisal guidance
    Published
    4 September 2024
    View recommendations

    Sections for TA999

  3. Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730

    Awaiting development [GID-TA11105] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

    NICE guideline
    Last updated
    24 June 2019
    View recommendations

    Sections for NG123

  5. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

    NICE guideline
    Published
    20 June 2018
    View recommendations

    Sections for NG97